6 November 2017 - Approval builds on existing adult monotherapy and adjunctive therapy indications, broadening clinical application for Vimpat tablets and oral solution.

Today, UCB announced that the U.S. FDA has approved a label extension for the company’s anti-epileptic drug Vimpat (lacosamide) CV as an oral option for the treatment of partial-onset seizures in paediatric patients four years and older.

This new approval provides clinicians with the option to prescribe Vimpat to their paediatric patients either as an oral solution or a convenient tablet. This allows for flexible administration options, an important consideration when treating children. As the safety of Vimpat injection has not been established in paediatric patients, Vimpat injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).

Read UCB press release